Pre-earnings brief
Reports
Thu, May 7, 2026
Est. EPS
$-1.02
Est. revenue
$6M
Implied move
±0.2%
EPS beat rate
50%
Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs in oncology, a field that continues to evolve with new technologies and treatments.
Last quarter
In the last quarter, Arcellx reported an EPS of -4.07, significantly missing expectations. The stock saw a slight increase of 0.11% the following day, indicating a mixed market reaction.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-36.35%
Avg 1-day reaction
+2.14%
Analysts are anticipating a challenging quarter for Arcellx, with expected losses continuing. The consensus EPS of -1.02 suggests ongoing financial struggles.
Bull case
If Arcellx can exceed revenue expectations and show signs of improving its product pipeline, it could indicate a turnaround and boost investor confidence.
Bear case
Continued losses and failure to meet revenue targets could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.
Key metrics to watch
EPS
-1.02Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
6MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the revenue reach or exceed the consensus estimate of $6M?
Revenue performance is critical for assessing the company's market traction and ability to generate sales.
Q2
How will management address the ongoing losses reflected in the expected EPS of -1.02?
Investors will be looking for a clear strategy to improve profitability and manage costs moving forward.
Why consensus could be wrong
The Street may underestimate the potential for Arcellx's pipeline to yield unexpected positive results, as recent advancements in their therapies could drive revenue growth.
Supporting evidence
The company has a history of surprising on earnings, with a 50% beat rate in the last eight quarters.
Options pricing suggests low volatility expectations, which may not reflect the potential for significant developments.
Recent advancements in biotechnology could position Arcellx favorably against competitors.
Key risk
If revenue exceeds $6M, it could challenge the current bearish sentiment and shift investor outlook.
Pre-commit to what would confirm each case.
The market is weighing the company's ability to recover from previous losses and meet revenue expectations amidst ongoing challenges.
Bull confirmed if
Achieving revenue above $6M would confirm a positive outlook for the company's growth potential.
Bear confirmed if
Falling short of the $6M revenue target could solidify concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±0.15%
Historical Avg
±2.3%
The options market is pricing in a very modest move, suggesting that investors are not expecting significant volatility around the earnings report.
Options are pricing ±0.2% while ACLX has averaged ±2.3% over the last 8 prints — setup is pricing cheap.
ATM IV
0.0%
30d HV
1.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Arcellx beats expectations, history suggests the stock could rise by about 2.88%, confirming a positive shift in market sentiment.
In line / cautious
A cautious in-line report may lead to muted reactions, as investors assess management's commentary on future prospects.
Miss
If the company misses estimates, history suggests a potential decline of around 1.40%, reflecting ongoing investor concerns.
The lines on the call that would change the story.
—
Est. EPS
$0.24
Est. Rev
$101M
Impl. Move
±11.2%